Encompass Health Corp. Hits New 52-Week High at $127.86

Encompass Health Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 127.86 on September 23, 2025. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 47.48%, significantly outpacing the S&P 500's growth of 17.38% during the same period.
The company's market capitalization stands at USD 14,505 million, reflecting its position within the small-cap category. Encompass Health Corp. boasts a price-to-earnings (P/E) ratio of 21.00, indicating a solid valuation relative to its earnings. Additionally, the company offers an impressive dividend yield of 23.73%, which may appeal to income-focused investors.

With a debt-to-equity ratio of 0.89 and a return on equity of 30.38%, Encompass Health demonstrates a balanced financial structure and effective management of shareholder equity. The stock's previous 52-week low was recorded at USD 87.85, highlighting the significant upward movement in its price. This recent performance positions Encompass Health Corp. as a noteworthy entity in the pharmaceuticals and biotechnology landscape.